The efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy
| ISRCTN | ISRCTN57145331 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN57145331 |
| EudraCT/CTIS number | 2020-002242-17 |
| IRAS number | 283265 |
| ClinicalTrials.gov number | NCT04706429 |
| Secondary identifying numbers | CPMS 45988, IRAS 283265 |
- Submission date
- 28/07/2020
- Registration date
- 07/09/2020
- Last edited
- 15/01/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition. It leads to abnormal thickening and scarring of the walls of the heart. As a result, the heart can have trouble pumping blood as well as it should. This causes patients to develop breathing difficulties, chest pain, and fainting, which often get worse with exercise, and therefore can limit physical activity. Current treatments only aim to relieve the symptoms. There are no treatments that correct the underlying damage to the heart. Patients, caregivers, and researchers have identified a “critical need” for trials of medicines that target the HCM disease process.
Several studies in other diseases have shown that copper imbalance is associated with heart thickening similar to HCM, and that treatment with trientine, an oral medicine that increases copper removal in urine, can reverse this thickening.
This study will investigate whether trientine reduces heart muscle thickening, improves exercise capacity, improves heart function, and reduces abnormal heart rhythms in patients with HCM. The study will also assess how trientine works in HCM.
This research study aims to recruit 152 patients with HCM aged 18-75 years in the UK. Participants in the study will be prescribed either trientine or placebo for 1 year to compare the difference.
Who can participate?
Patients with hypertrophic cardiomyopathy aged 18-75 years can participate
What does the study involve?
If patients agree to take part, they will be asked to sign a consent form. Once the consent form is signed, the trial team will check and confirm that this study is suitable for the patient. If it is, they will be entered into the study. Participants will be randomly assigned to receive either trientine or a dummy pill.
Participants will be in the study for 1 year. During this time, they will be asked to attend the hospital for 6 visits. Study tests include blood tests, urine test, heart trace (ECG), heart magnetic resonance imaging (MRI scan of the heart), 24-hour heart monitor, exercise test and pregnancy test if female and of childbearing age. A subgroup of participants will undergo an extra MRI scan.
What are the possible benefits and risks of participating?
Participants will receive closer follow-up than they would usually have and have more access to heart specialists than normal. They may have a more detailed assessment of their heart than they usually would.
Participants will help to determine whether trientine will be of benefit to other patients with HCM and will also contribute to a better understanding of HCM in general. This may lead to benefits for the participant and other people.
Trientine has been used in Wilson disease for more than 30 years. It is safe and well tolerated. Between 1-in-100 and 1-in-10 people experience nausea on starting trientine and between 1-in-1000 and 1-in-100 people develop a skin rash. Trientine can reduce blood iron levels. Between 1-in-1000 and 1-in-100 people develop anaemia (low blood iron level). Iron levels and blood counts will be monitored during the study. Iron supplementation in the form of tablets may be necessary in some cases. There have been isolated case reports of trientine being associated with inflammation of the bowel. All of the possible side effects resolve on reducing the dose or stopping it and are not associated with long-term effects.
Where is the study run from?
Manchester University NHS Foundation Trust (UK) and three other NHS foundation trusts in the UK
When is the study starting and how long is it expected to run for?
From July 2018 to April 2024
Who is funding the study?
The National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) Programme (UK)
Who is the main contact?
Mrs Carly Vaughan
tempest@liverpool.ac.uk
Contact information
Scientific
Wythenshawe Hospital
Cardiology Department
Southmoor Road
Roundthorn Industrial Estate
Wythenshawe
Manchester
M23 9LT
United Kingdom
| Phone | +44 (0)161 291 2034 |
|---|---|
| christopher.miller@manchester.ac.uk |
Study information
| Study design | Multicentre interventional randomized controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details (tempest@liverpool.ac.uk) to request a participant information sheet’ |
| Scientific title | A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy |
| Study acronym | TEMPEST |
| Study objectives | Trientine will reduce LV mass, which will be associated with improved exercise capacity, reduced arrhythmia burden, and improved cardiac function. The reduction in LV mass will be mediated by a reduction in myocardial cellular mass and fibrosis and improved myocardial energetics, which will be determined by increased copper excretion. |
| Ethics approval(s) | Approved 21/07/2020, Greater Manchester South Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)2071048127; gmsouth.rec@hra.nhs.uk), ref: 20/NW/0275 |
| Health condition(s) or problem(s) studied | Hypertrophic cardiomyopathy |
| Intervention | The study will last for 1 year and involves 6 visits to the hospital. The initial visit will have a number of assessments including a review of medical history, review of medications, pulse, blood pressure, height and weight, blood tests, ECG, 24 h heart monitor, and a pregnancy test, if applicable. If the assessments performed at Visit 1 show that the patient is eligible for the study, Visit 2 will be arranged within 4 weeks for the patient to be randomised. Participants will be randomised to receive either trientine (two 200 mg capsules, twice daily, 800 mg/day total) or placebo, in a 1:1 ratio. Block randomisation, stratified by site, will be implemented, with computer generated randomisation allocations and randomly varying block sizes. The randomisation code will be generated by an independent LCTC statistician who is not involved with this trial. At Visit 2 a review of medications, blood test, urine test, exercise test, and a pregnancy test, if applicable, will take place. Participants will also have an MRI scan of the heart known as cardiovascular magnetic resonance (CMR) scan. A subgroup of participants will undergo an extra MRI scan called phosphorus magnetic resonance spectroscopy (31P MRS). Study medication will be dispensed by the pharmacy at visits 2, 3, 4, and 5. Visits 3, 4, and 5 will take place 13 weeks apart. At these visits all current medications are reviewed, measurements of pulse, blood pressure, height, and weight are taken. There will be a review of safety, compliance, and review of the patient's diary. An ECG, blood, and urine test are also performed, as well as a pregnancy test, if applicable. Visit 6 will include the same tests as visits 3, 4, and 5, with the addition of height and weight, an MRI scan, 24 h heart monitor, and the exercise test. The subgroup will undergo 31P MRS. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase II |
| Drug / device / biological / vaccine name(s) | Trientine (Triethylinetetramine dihydrochloride) |
| Primary outcome measure | Change in left ventricular mass index (LVMi, g/m2) is measured using a cardiovascular magnetic resonance (CMR) scan at baseline and week 52 |
| Secondary outcome measures | 1. Cumulative urine copper excretion is measured using urinary copper in urine samples given at baseline, 13, 26, 39 and 52 weeks 2. Change in exercise capacity is measured using cardiopulmonary exercise testing (CPET) at baseline and week 52 3. Change in number of non-sinus supraventricular heartbeats, presence and amount of atrial fibrillation, number of ventricular-origin beats, and presence and amount of non-sustained ventricular tachycardia, in 24 h is measured using ambulatory ECG heart monitoring at baseline, 13, 26, 39 and 52 weeks 4. Change in circulating high sensitivity troponin measured from blood samples given at baseline, 13, 26, 39 and 52 weeks 5. Change in LV global longitudinal strain, wall thickness, mass, volumes, and ejection fraction (EF) is measured using CMR at baseline and week 52 (Updated 07/11/2023 to remove strain rate) 6. Change in peak left ventricular outflow tract gradient is measured using CMR at baseline and week 52 7. Change in atrial volume and function is measured using CMR at baseline and week 52 |
| Overall study start date | 01/07/2018 |
| Completion date | 30/04/2024 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 75 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 152; UK Sample Size: 152 |
| Total final enrolment | 154 |
| Key inclusion criteria | 1. Written informed consent given 2. Aged between 18 and 75 years inclusive (Updated 07/11/2023: previously between 18 and 70 years inclusive) 3. Hypertrophic cardiomyopathy (HCM), as defined by the European Society of Cardiology HCM guidelines as: “a wall thickness > = 15 mm in one or more LV myocardial segments that is not explained solely by loading conditions”. The same definition is applied to first-degree relatives of patients with HCM i.e. all participants are required to have a LV wall thickness > = 15 mm. Wall thickness is as measured on the most recent cardiovascular magnetic resonance (CMR) scan performed prior to the baseline visit. If CMR has not been performed previously, wall thickness measurement should be taken from the most recent echocardiogram performed prior to the baseline visit. (It is recognised that in the European Society of Cardiology guidelines a clinical diagnosis of HCM in first-degree relatives requires a wall thickness that is less than this value, however > = 15 mm is applied here in order to ensure that all participants have an unequivocal phenotype). 4. New York Heart Association class I, II or III at the most recent clinical assessment performed prior to the baseline visit |
| Key exclusion criteria | 1. Previous or planned septal reduction therapy 2. Previously documented myocardial infarction or severe coronary artery disease 3. Uncontrolled hypertension, defined as a systolic blood pressure of >180 mmHg or diastolic blood pressure of >100 mmHg at visit 1 4. Known LV EF <50%, as measured on the most recent CMR scan performed prior to the baseline visit. If CMR has not been performed previously, the most recent echocardiogram performed prior to the baseline visit should be used. 5. Previously documented persistent atrial fibrillation 6. Anaemia, defined as haemoglobin being below the local site normal reference range, at visit 1 7. Iron deficiency, defined as serum iron being below the local site normal reference range, at visit 1 8. Copper deficiency, defined as serum copper being below the normal reference range, at visit 1 9. Pacemaker or implantable cardioverter-defibrillator 10. Known severe valvular heart disease, as demonstrated on the most recent heart imaging performed prior to the baseline visit 11. Previously documented other cardiomyopathic cause of myocardial hypertrophy (e.g. amyloidosis, Fabry disease, mitochondrial disease) 12. History of hypersensitivity to any of the components of the investigational medicinal product (IMP) 13. Known contraindication to MRI scanning 14. Pregnancy, lactation, or planning pregnancy. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment, must agree to pregnancy tests at study visits as defined in the Section 8, and must agree to maintain highly effective contraception as defined in Section 8 during the study. 15. Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study |
| Date of first enrolment | 29/03/2021 |
| Date of final enrolment | 30/04/2023 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Liverpool
L14 3PE
United Kingdom
Southmoor Road
Manchester
M23 9LT
United Kingdom
Headley Way
Headington
Oxford
OX3 9DU
United Kingdom
Sydney Street
London
SW3 6NP
United Kingdom
Groby Road
Leicester
LE3 9QP
United Kingdom
Aberdeen
AB25 2ZN
United Kingdom
Ashington
Northumberland
NE29 8NH
United Kingdom
Sponsor information
Hospital/treatment centre
Cobbett House
Oxford Road
Manchester
M13 9WL
England
United Kingdom
| Phone | +44 (0)161 276 3565 |
|---|---|
| lynne.webster@mft.nhs.uk | |
| Website | https://mft.nhs.uk/ |
"ROR" |
https://ror.org/00he80998 |
Funders
Funder type
Government
No information available
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 01/09/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | The results of the trial will be disseminated as early as possible in order to appropriately inform policy and practice. This will include academic journal publications and presentations at academic conferences, Lay summaries of the study findings will be posted to the trial website and links to these summaries will be posted on patient group websites. Presentations will be made to patient groups and a symposium that brings together key stakeholders will be held. |
| IPD sharing plan | The data-sharing plans for the current study are unknown and will be made available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol file | version v2.0 | 09/07/2020 | 11/12/2020 | No | No |
| Protocol article | 03/05/2023 | 04/05/2023 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No | ||
| Protocol file | version 5.0 | 25/08/2023 | 07/11/2023 | No | No |
Additional files
- ISRCTN57145331_PROTOCOL_v2.0_09July2020.pdf
- uploaded 11/12/2020
- ISRCTN57145331_PROTOCOL_V5.0_25Aug23.pdf
Editorial Notes
15/01/2025: The intention to publish date was changed from 01/12/2024 to 01/09/2025. Total final enrolment added.
07/11/2023: The following changes were made to the study record:
1. Protocol file uploaded.
2. The target number of participants was changed from 172 to 152.
3. The inclusion criteria and secondary outcome measures were updated.
4. The recruitment end date was changed from 01/12/2022 to 30/04/2023.
5. University Hospitals of Leicester NHS Foundation Trust, NHS Grampian and Northumbria Healthcare NHS Foundation Trust were added as study participating centres.
6. The overall study end date was changed from 01/12/2023 to 30/04/2024.
04/05/2023: Publication reference added.
20/04/2021: The recruitment start date was changed from 01/02/2021 to 29/03/2021.
12/02/2021: ClinicalTrials.gov number added.
11/12/2020: The following changes were made to the trial record:
1. The recruitment start date was changed from 01/12/2020 to 01/02/2021.
2. Uploaded protocol (not peer reviewed) Version 2.0 09 July 2020.
29/07/2020: Trial’s existence confirmed by the National Institute for Health Research (NIHR).
